で公開中です! 詳しく見る
0.3862 USD
-0.0137
3.43%
終値時点 更新済み 10月16日 16:00 EDT
プレマーケット
時間外取引
0.3938
+0.0076
1.97%
1日
-3.43%
5日間
-2.13%
1か月
-22.11%
3か月
-33.96%
6か月
-51.43%
年初来
-65.82%
1年
-69.83%
5年間
-98.5%
10年間
-99.37%
 

概要: Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.

従業員数: 52

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 0%
ニュートラル 100%
ネガティブ 0%
ニュートラル
PRNewsWire
10 日前
Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors
REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it has entered into a comprehensive cooperation agreement (the "Agreement") with L.I.A.
Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors
ニュートラル
PRNewsWire
17 日前
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- Evogene Ltd.
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
ニュートラル
PRNewsWire
先月
Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward
Company urges shareholders to evaluate the significant changes already implemented and vote FOR all Evogene nominees on September 4, 2026, Annual General Meeting REHOVOT, Israel, Aug. 31, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today responded to the latest communication from dissident shareholders L.I.A.
Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward
ニュートラル
Seeking Alpha
先月
EverGen Infrastructure Corp. (EVGN:CA) Q2 2026 Earnings Call Transcript
EverGen Infrastructure Corp. (EVGN:CA) Q2 2026 Earnings Call Transcript
EverGen Infrastructure Corp. (EVGN:CA) Q2 2026 Earnings Call Transcript
ニュートラル
Business Wire
先月
EverGen Infrastructure Announces Voting Results for the Annual General Meeting of Shareholders Held on August 25, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN), is pleased to report the voting results from its Annual General Meeting of Shareholders (“AGM”) held on August 25, 2026. A total of 16,172,472 common shares were represented at the meeting, representing 62.43% of the Company's outstanding shares. The following is a summary of the proxy voting results for the AGM. 1. Election of Directors The following individuals were elected as.
EverGen Infrastructure Announces Voting Results for the Annual General Meeting of Shareholders Held on August 25, 2026
ニュートラル
Seeking Alpha
先月
EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript
EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript
EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript
ニュートラル
PRNewsWire
先月
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees
Recommendations Reinforce Confidence in Evogene's Strategic Plan and Long-Term Value Creation Strategy  Board Urges Shareholders to Vote FOR All Evogene Nominees, and to disregard the Pure Capital Nominees, at the September 4, 2026, Annual General Meeting REHOVOT, Israel, Aug. 25, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that leading independent proxy advisory firms Institutional Shareholder Services ("ISS") and Glass Lewis have recommended that Evogene shareholders vote "FOR" the Company slate of nominees in connection with the September 4, 2026 Annual General Meeting of Shareholders.
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees
ニュートラル
Seeking Alpha
先月
Evogene Ltd. (EVGN) Q2 2026 Earnings Call Transcript
Evogene Ltd. (EVGN) Q2 2026 Earnings Call Transcript
Evogene Ltd. (EVGN) Q2 2026 Earnings Call Transcript
ニュートラル
PRNewsWire
先月
Evogene Reports Second Quarter and First Half 2026 Financial Results
Company continues strategic transformation, initiated in 2025, into a focused, AI-driven computational chemistry company, with significant progress across pharmaceutical and agricultural product development programs Cash burn expected to decline to approximately $8.5–$9.5 million in 2026, compared with approximately $14.4 million in 2025 and approximately $20.5 million in 2024  Second-quarter net loss was reduced to approximately $1.8 million, compared with approximately $4.7 million in the second quarter of 2025 and approximately $6.0 million in the second quarter of 2024 Six active drug development collaborations established with biotechnology companies and leading academic institutions Virtual chemical space expanded to approximately 110 billion molecules, supported by advanced AI models and autonomous AI Agents REHOVOT, Israel, Aug. 18, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the first half of 2026 and second quarter ended June 30, 2026, and provided an update on its strategic and operational progress.
Evogene Reports Second Quarter and First Half 2026 Financial Results
ニュートラル
PRNewsWire
2 か月前
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
Zoom conference call scheduled for August 18, 2026, at 9:00 AM ET REHOVOT, Israel, Aug. 14, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that its Chairman, Nir Nimrodi, will join the Company's upcoming quarterly results conference call on August 18, 2026.
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
価格チャートは Lightweight Charts™ を使用して実装されています